AstraZeneca, the UK-based pharmaceutical company, has engaged in discussions with US counterpart Bristol Myers Squibb regarding a potential merger that could form a pharmaceutical entity valued at nearly $400 billion (£297 billion). These talks, which have reportedly taken place over several months, signal the possibility of one of the largest mergers in the history of the pharmaceutical industry.

Details of the negotiations remain limited as both companies have yet to confirm the status or terms of the potential deal. Industry analysts suggest that such a combination would significantly reshape the global pharmaceutical landscape by combining AstraZeneca’s strong portfolio, including its recent advances in oncology and respiratory treatments, with Bristol Myers Squibb’s established presence in cancer therapies and immunology.

If completed, the merger would create a new leader in drug development and commercialisation, enhancing the ability of the combined group to compete with other pharmaceutical giants on research, innovation, and market reach. Both companies have been under pressure to drive growth amid rising competition and patent expirations affecting key products.

Market watchers note that regulatory approval could pose a significant challenge due to the size and global reach of the combined firm, with antitrust concerns likely to be scrutinized by authorities in multiple jurisdictions.

Neither AstraZeneca nor Bristol Myers Squibb has commented publicly on the specific merits or timeline of the discussions, and it remains unclear how close the companies are to reaching a formal agreement. Should the merger proceed, it would mark a major consolidation within the pharmaceutical sector and signal ongoing shifts in strategy as firms seek scale and diversification in an increasingly competitive industry.